LABELS · a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f

Stoboclo

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-02-05
Captured: 2026-09-09T23:37:54.830918+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions (5.1) ] . Prior to initiating Stoboclo in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Stoboclo in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ] WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. ( 5.1 ) The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia. ( 5.1 ) Prior to initiating Stoboclo in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Stoboclo in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD. ( 2.2 ), ( 5.1 )

Indications and usage: exact source text

1 INDICATIONS AND USAGE Stoboclo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Stoboclo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Stoboclo is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Stoboclo is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Stoboclo is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Stoboclo is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .

Full extracted label fields

application numbers

BLA761404

boxed warning exact

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions (5.1) ] . Prior to initiating Stoboclo in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Stoboclo in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ] WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. ( 5.1 ) The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia. ( 5.1 ) Prior to initiating Stoboclo in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Stoboclo in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD. ( 2.2 ), ( 5.1 )

brand names

Stoboclo

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10b9eea3-bf70-4ff3-a0b9-54248cbfd156

generic names

DENOSUMAB-BMWO

a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f

indications and usage exact

1 INDICATIONS AND USAGE Stoboclo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Stoboclo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Stoboclo is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Stoboclo is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Stoboclo is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Stoboclo is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .

indications and usage tables exact

is original packager

true

manufacturer names

CELLTRION USA, Inc.

matched search terms

cancer

package ndcs

72606-037-01

product ndcs

72606-037

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

2717855
2717862

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00500.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

BLA761404

brand names

Stoboclo

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 368
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Stoboclo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 0

current approval status

not_reconciled

duplicate text group

dup-4fef5db1a10325bdbed9

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-f3a27cd61d9411e8e657

label id

a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f

positive predicate support span

end: 77
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 33

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 168
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Stoboclo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 )
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f%22

spl effective date

2026-02-05

spl set id

10b9eea3-bf70-4ff3-a0b9-54248cbfd156

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · positive indication candidate

application numbers

BLA761404

brand names

Stoboclo

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 449
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Stoboclo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastat
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 0

current approval status

not_reconciled

duplicate text group

dup-0483e93d722a60b26dc4

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-9da27b68b651b84cfc27

label id

a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f

positive predicate support span

end: 77
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 33

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 249
end exclusive: true
exact text: to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 )
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 169

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f%22

spl effective date

2026-02-05

spl set id

10b9eea3-bf70-4ff3-a0b9-54248cbfd156

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 3 · unclassified context

application numbers

BLA761404

brand names

Stoboclo

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 539
end exclusive: true
exact text: (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiv
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 50

current approval status

not_reconciled

duplicate text group

dup-49c957bcd9fe96c25747

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-8714649d68b84f99e6e3

label id

a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 339
end exclusive: true
exact text: of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 )
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 250

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f%22

spl effective date

2026-02-05

spl set id

10b9eea3-bf70-4ff3-a0b9-54248cbfd156

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

BLA761404

brand names

Stoboclo

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 675
end exclusive: true
exact text: gh risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 140

current approval status

not_reconciled

duplicate text group

dup-acae84b0c5dfa98f6bec

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-63eb92f8481871d7708b

label id

a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f

positive predicate support span

end: 77
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 33

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 475
end exclusive: true
exact text: to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 )
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 340

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f%22

spl effective date

2026-02-05

spl set id

10b9eea3-bf70-4ff3-a0b9-54248cbfd156

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 5 · positive indication candidate

application numbers

BLA761404

brand names

Stoboclo

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 805
end exclusive: true
exact text: osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Stoboclo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 276

current approval status

not_reconciled

duplicate text group

dup-2c34168758a4db879bb7

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-e22b1f72f2b8c83a3cf0

label id

a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f

positive predicate support span

end: 77
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 33

qualifier mentions

context exact
ease bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 )
kind
stage_or_setting
polarity
not_inferred
span
end
586
end exclusive
true
exact text
adjuvant aromatase inhibitor therapy for br
label id
a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start
543

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 605
end exclusive: true
exact text: to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 )
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 476

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f%22

spl effective date

2026-02-05

spl set id

10b9eea3-bf70-4ff3-a0b9-54248cbfd156

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 6 · positive indication candidate

application numbers

BLA761404

brand names

Stoboclo

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1169
end exclusive: true
exact text: ndrogen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Stoboclo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men wi
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 406

current approval status

not_reconciled

duplicate text group

dup-0f0f24fbbf8bea4d9037

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-fdc19fe172a2d3959df1

label id

a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f

positive predicate support span

end: 709
end exclusive: true
exact text: is indicated
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 697

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 969
end exclusive: true
exact text: 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Stoboclo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 606

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f%22

spl effective date

2026-02-05

spl set id

10b9eea3-bf70-4ff3-a0b9-54248cbfd156

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 7 · unclassified context

application numbers

BLA761404

brand names

Stoboclo

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1323
end exclusive: true
exact text: at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Stoboclo is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of oste
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 770

current approval status

not_reconciled

duplicate text group

dup-a0c765cad7671c501420

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-376ad6bb23ad31aa1850

label id

a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 1123
end exclusive: true
exact text: In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] .
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 970

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f%22

spl effective date

2026-02-05

spl set id

10b9eea3-bf70-4ff3-a0b9-54248cbfd156

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

BLA761404

brand names

Stoboclo

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1699
end exclusive: true
exact text: rant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Stoboclo is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Stoboclo is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 924

current approval status

not_reconciled

duplicate text group

dup-14151460f8efdc92852e

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-f53a622abb96f9bc4820

label id

a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f

positive predicate support span

end: 1206
end exclusive: true
exact text: is indicated
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 1194

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 1499
end exclusive: true
exact text: 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Stoboclo is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] .
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 1124

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f%22

spl effective date

2026-02-05

spl set id

10b9eea3-bf70-4ff3-a0b9-54248cbfd156

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 9 · positive indication candidate

application numbers

BLA761404

brand names

Stoboclo

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
positive_statement_also_contains_qualification_review_required

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2067
end exclusive: true
exact text: ed as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Stoboclo is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 1300

current approval status

not_reconciled

duplicate text group

dup-566ed3f95357d6acb8aa

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-fc4ba8151bc8006d352c

label id

a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f

positive predicate support span

end: 1574
end exclusive: true
exact text: is indicated
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 1562

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 1867
end exclusive: true
exact text: 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Stoboclo is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months.
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 1500

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f%22

spl effective date

2026-02-05

spl set id

10b9eea3-bf70-4ff3-a0b9-54248cbfd156

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 10 · risk or warning

application numbers

BLA761404

brand names

Stoboclo

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 2294
end exclusive: true
exact text: cture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Stoboclo is indicated as a treatment to increase bone mass in men at high risk for fracture receiving andr
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 1668

current approval status

not_reconciled

duplicate text group

dup-48c9c2fcfc67c8026e14

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-14f9ffe6f9bc65eddfb8

label id

a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 2094
end exclusive: true
exact text: High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] .
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 1868

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f%22

spl effective date

2026-02-05

spl set id

10b9eea3-bf70-4ff3-a0b9-54248cbfd156

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 11 · positive indication candidate

application numbers

BLA761404

brand names

Stoboclo

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2559
end exclusive: true
exact text: fined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Stoboclo is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for B
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 1895

current approval status

not_reconciled

duplicate text group

dup-61e9e9719b988b82bb36

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-cf336a13f61b1eb2c967

label id

a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f

positive predicate support span

end: 2209
end exclusive: true
exact text: is indicated
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 2197

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 2359
end exclusive: true
exact text: 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Stoboclo is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer.
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 2095

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f%22

spl effective date

2026-02-05

spl set id

10b9eea3-bf70-4ff3-a0b9-54248cbfd156

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 12 · unclassified context

application numbers

BLA761404

brand names

Stoboclo

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2670
end exclusive: true
exact text: Therapy for Prostate Cancer Stoboclo is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Stoboclo is indicated as a treatment to increase bone mass in women at high risk for fracture rece
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 2160

current approval status

not_reconciled

duplicate text group

dup-1424204f4bcd5085fa31

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-0da3a186f1b69c2cf67a

label id

a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 2470
end exclusive: true
exact text: In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] .
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 2360

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f%22

spl effective date

2026-02-05

spl set id

10b9eea3-bf70-4ff3-a0b9-54248cbfd156

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · positive indication candidate

application numbers

BLA761404

brand names

Stoboclo

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2763
end exclusive: true
exact text: fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Stoboclo is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 2271

current approval status

not_reconciled

duplicate text group

dup-3bb432f7199df929a59f

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-fbe755c1649de6c9d4a5

label id

a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f

positive predicate support span

end: 2593
end exclusive: true
exact text: is indicated
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 2581

qualifier mentions

context exact
1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Stoboclo is indicated as a treatment to increase
kind
stage_or_setting
polarity
not_inferred
span
end
2560
end exclusive
true
exact text
Adjuvant Aromatase Inhibitor Therapy for Br
label id
a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start
2517
context exact
ease bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
kind
stage_or_setting
polarity
not_inferred
span
end
2719
end exclusive
true
exact text
adjuvant aromatase inhibitor therapy for br
label id
a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start
2676

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 2763
end exclusive: true
exact text: 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Stoboclo is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
label id: a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 2e370a7d9dab5c70f52f29989b8d496b70c0430d4229c34cb9db14ec26a5fa1f
start: 2471

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49f%22

spl effective date

2026-02-05

spl set id

10b9eea3-bf70-4ff3-a0b9-54248cbfd156

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Preserved source evidence · Not medical advice